Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Sorafenib|DRUG: Ixabepilone
Sponsor: SCRI Development Innovations, LLC
Collaborators: Bayer|Bristol-Myers Squibb